MAPT and Alzheimer disease: Two‐phase III trials of Bapineuzumab in AD displayed the same result: although Bapineuzumab did not change the overall clinical outcome in patients with AD, improvements in markers related to hyperphosphorylated Tau and amyloid plaque deposition were observed in APOE4 carriers [135].